NextCell and Cellaviva are highlighted by KI Innovations
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social benefits that research of KI has contributed during the past 20 years.
Cellaviva was founded by researchers at Karolinska Institutet with help from Karolinska Institutet Innovations AB. The company became the first private stem cell bank in Sweden, which in recent years has been further developed into NextCell Pharma AB, a stem cell company that continues to manage the stem cell bank under the name Cellaviva and now also develops new stem cell treatments.
From research at the Karolinska Institute, a number of innovative products and solutions have emerged which contribute to great benefits, both nationally and internationally. To pay attention to this and to highlight the power and creativity of the innovation world at KI, Karolinska Institutet Innovations AB organizes a seminar in the theme of “20 years of Innovation @Karolinska Institutet”.
During the morning, research and inventions made at KI, which in various ways have contributed to increasing the amount of knowledge and the power of innovation in society, will be presented. KI Innovations also wants to inspire a continued competitive ecosystem for Life Science in Sweden by highlighting 20 inventions in a printed format that in the last 20 years have uniquely contributed to social benefits. These are presented in the book "20 years of innovation @ Karolinska Institutet" which is launched in connection with the seminar on March 29. CEO Mathias Svahn has been invited to the seminar to receive a signed copy of the book by the president of Karolinska Institutet, Ole Petter Ottersen.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.